These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 28605233)

  • 1. Clinoptilolite for Treatment of Dyslipidemia: Preliminary Efficacy Study.
    Cutovic M; Lazovic M; Vukovic-Dejanovic V; Nikolic D; Petronic-Markovic I; Cirovic D
    J Altern Complement Med; 2017 Sep; 23(9):738-744. PubMed ID: 28605233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
    Foucher C; Aubonnet P; Reichert P; Berli M; Schaeffer A; Calvo Vargas CG; Lochocka A; Belenky D; Koch HF;
    Cardiovasc Ther; 2015 Dec; 33(6):329-37. PubMed ID: 26227087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study on the ability of clinoptilolite to absorb ethanol in vivo in healthy drinkers: effect of gender.
    Federico A; Dallio M; Gravina AG; Iannotta C; Romano M; Rossetti G; Somalvico F; Tuccillo C; Loguercio C
    J Physiol Pharmacol; 2015 Jun; 66(3):441-7. PubMed ID: 26084226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T; Caso R; McMahon D; Nymark M
    Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary supplementation with the tribomechanically activated zeolite clinoptilolite in immunodeficiency: effects on the immune system.
    Ivkovic S; Deutsch U; Silberbach A; Walraph E; Mannel M
    Adv Ther; 2004; 21(2):135-47. PubMed ID: 15310086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study.
    Nejat A; Mirbolouk M; Mohebi R; Hasheminia M; Tohidi M; Saadat N; Azizi F; Hadaegh F
    Clin Biochem; 2014 Sep; 47(13-14):1239-44. PubMed ID: 24657509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of dyslipidemia and associated risk factors in Turkish adults.
    Bayram F; Kocer D; Gundogan K; Kaya A; Demir O; Coskun R; Sabuncu T; Karaman A; Cesur M; Rizzo M; Toth PP; Gedik V
    J Clin Lipidol; 2014; 8(2):206-16. PubMed ID: 24636181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S; Gamez R; Mas R; Goicochea E
    Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiological survey of lipid levels and factors in Kazakan people over 30-year old in Fukang of Xinjiang].
    Liang DP; Yao XG; Li NF; Zhang DL; Guo YY; Lin L; Zhou L; Li WC; Yan ZT; Wang HM; Luo WL; Chang JH
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 May; 45(5):440-3. PubMed ID: 21756789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cross-sectional study of the association between circulating TSH level and lipid profile in a large Spanish population.
    Santos-Palacios S; Brugos-Larumbe A; Guillén-Grima F; Galofré JC
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):874-81. PubMed ID: 23550997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plasma lipid level and incidence of dyslipidemia in workers of Chongqing enterprises and institutions].
    Gao Y; Zhong XN; Yang YH; Tian KC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 May; 40(5):432-5. PubMed ID: 22883098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.